5 Top NASDAQ Biotech Stocks: Neovasc Wins the Week
Neovasc, Arbutus Biopharma, Aralez Pharmaceuticals, CASI Pharmaceuticals and Nabriva Therapeutics top the NASDAQ biotech stock list.
Your trusted source for investing success
Your trusted source for investing success
Originally from Mexico, Bryan moved to Vancouver and obtained a diploma in journalism from Langara College. He covers Life Science for Investing News Network. You can usually find him watching basketball or trying to finish news magazines.
Neovasc, Arbutus Biopharma, Aralez Pharmaceuticals, CASI Pharmaceuticals and Nabriva Therapeutics top the NASDAQ biotech stock list.
The Investing News rounds some of the biggest news in the cannabis market for the past trading week
The Canadian Securities Exchange launched a new index meant to account for the largest companies on the exchange, some of the top weighing companies in the index operate in the cannabis business.
What if the “one-size-fits-all” approach to medicine isn’t the right way treat medical conditions? Could a personalized medicine approach provide better treatment?
Alternate Health announced the company was ranked fourth amongst its peers on the CSE 25 Index.
InMed Pharmaceuticals announced that it has been included in the CSE25 Index.
Savaria announced the appointment of Caroline Bérubé as director of the board of directors of the corporation.
Breathtec Biomedical announced the resignation of director and chief executive officer.
InspireMD announced it has signed an agreement with Medicinália Cormédica MC Medical Lda, a medical distributor in Portugal, to distribute CGuard EPS.
Sirona Biochem provided an update to shareholders from their chief financial officer Dr. Howard Verrico.
Spectral Medical announced it has been engaged in an ongoing interactive review process with the FDA, after its acceptance submission for Toraymyxin.
American Cannabis signed an exclusive distribution agreement with Earth Alive, a clean-tech company developing microbial technology-based products.
BioCryst Pharmaceuticals announced the FDA approved a supplemental new drug application for RAPIVAB.
Lipocine announced that the Patent Trial and Appeal Board of the United States Patent and Trademark Office issued a Motions Decision based on each party’s motions in an interference case.
Krystal Biotech announced a presentation of preclinical data assessing the in vitro and in vivo delivery of HSV-1 mediated KB103 at an upcoming conference.
What kind of metrics can investors look for when it comes to the growth of their picks in the cannabis space?
Medical devices are differentiated three different ways. Here, the Investing News Network looks at class 3 medical devices.
Elite Pharmaceuticals filed an abbreviated new drug application with the FDA for a generic version of OxyContin.
International Stem Cell announced the completion of its preclinical studies in Traumatic Brain Injury program will position it to commence a Phase II clinical trial in Australia.
Emerald Health Therapeutics announced members of its scientific advisory team made a discovery showing the potential of tetrahydrocannabinolic acid to treat Huntington’s disease and other metabolic, neurodegenerative and neuroinflammatory diseases.
Send this to a friend
